ArticleJTCVS open2026
Metabolic changes and plasma glycine predict the risk of acute cellular rejection in heart transplantation.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Brain death in organ donors may trigger tissue injury that can negatively influence transplant outcome. We analyzed plasma metabolomic profiles in heart transplant donors and tested whether any donor metabolite may predict the risk of acute cellular rejection after heart transplantation. Methods: Plasma samples from 83 heart transplant donors and 20 healthy volunteers were profiled using quantitative targeted metabolomics of 102 metabolites. Plasma samples from another set of 48 heart transplant donors were used for validation. Results: The plasma levels of 24 metabolites representing 24% of the targeted metabolites were significantly altered in brain-dead heart transplant donors, compared with healthy controls. Alterations in the purine metabolism pathway were most prominent: adenine, xanthosine, allantoin, xanthine, and inosine monophosphate were upregulated, whereas adenosine monophosphate and adenosine were downregulated, indicating an energy metabolism shift and oxidative stress. Donor plasma glycine levels predicted the risk of acute cellular rejection (concordance = 0.74, area under the curve = 0.75; Conclusions: Targeted metabolomics revealed altered purine metabolism in brain-dead heart transplant donors, suggesting increased energy demand and oxidative stress. Donor plasma glycine was identified as a risk predictor for acute cellular rejection after heart transplantation and may serve as a donor-side biomarker to guide posttransplant risk stratification and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.